What is the agent of HIV?

What is the agent of HIV?

Causal agent Human immunodeficiency virus (HIV), a retrovirus is the causative agent for Acquired Immunodeficiency syndrome (AIDS). Two serologically and geographically distinct types, HIV-1 and HIV-2 have been identified.

What are HIV-1 protease inhibitors?

Protease inhibitors are one type of antiretroviral drug used to treat HIV. The goal of these drugs is to reduce the amount of HIV virus in the body (called the viral load) to levels that are undetectable. This slows the progression of HIV and helps treat symptoms.

What is HIV M group1?

The HIV-1 group M viruses predominate and are responsible for the AIDS pandemic. Group M can be further subdivided into subtypes based on genetic sequence data. Some of the subtypes are known to be more virulent or are resistant to different medications.

What are the types of HIV strains Characterised?

The group has nine named strains: A, B, C, D, F, G, H, J, and K. Some of these have sub-strains. Researchers find new strains all the time as they learn more about HIV-1 group M. The B strain is the most common in the U.S. Worldwide, the most common HIV strain is C.

What is an example of a protease inhibitor?

Examples of protease inhibitors include ritonavir, saquinavir, and indinavir. Single-agent therapy with a protease inhibitor can result in the selection of drug-resistant HIV.

What are the four types of agents of disease?

The four different categories of infectious agents are bacteria, viruses, fungi, and parasites. When studying these agents, researchers isolate them using certain characteristics: Size of the infectious agent. Biochemical characteristics.

What is the causative agent of syphilis?

Syphilis is a sexually transmitted disease (STD) caused by the bacterium Treponema pallidum.

What drugs inhibit viral proteases?

List of Protease inhibitors:

What was the first protease inhibitor?

The first protease inhibitor to be approved by the US Food and Drug Administration (FDA) was saquinavir, in December 1995, a mere 97 days after the FDA received its marketing application.